Suraksha Diagnostic's FY25 Profit Up by 33.95%
By Ankur Chandra | Updated at: May 31, 2025 07:30 PM IST
Mumbai, May 29, 2025 – Suraksha Diagnostic Limited (BSE: 544293 | NSE: SURAKSHA) has reported a solid financial performance for the year ended March 31, 2025. The company recorded significant growth in revenue and profits, expanded its operational footprint, and made a strategic acquisition to strengthen its maternal healthcare services.
FY25 Financial Overview (Consolidtaed)
| Metric | FY25 | FY24 | YoY Growth |
|---|---|---|---|
| Total Income (₹ Mn) | 2,559.39 | 2,222.59 | 15.15% |
| EBITDA (₹ Mn) | 850.88 | 736.18 | 15.58% |
| EBITDA Margin (%) | 33.8% | 33.7% | +10 bps |
| PAT (₹ Mn) | 309.78 | 231.26 | 33.95% |
| PAT Margin (%) | 12.3% | 10.6% | +170 bps |
| EPS (₹) | 5.97 | 4.43 | 34.75% |
Q4 FY25 Snapshot
| Metric | Q4 FY25 | Q4 FY24 | YoY Growth |
|---|---|---|---|
| Total Income (₹ Mn) | 659.12 | 561.67 | 17.35% |
| EBITDA (₹ Mn) | 200.05 | 204.48 | -2.17% |
| PAT (₹ Mn) | 71.71 | 63.21 | 13.44% |
Strategic Expansion
In April 2025, Suraksha acquired a 63% stake in Fetomat Wellness Pvt. Ltd., a leading fetal and maternal care provider in Eastern India. This acquisition strengthens Suraksha’s prenatal diagnostic offerings and enhances its clinical scope.
Operational Highlights
- Tests Performed: 6.69 million
- Patients Served: 1.19 million
- Revenue Per Patient: ₹2,118
- EBITDA Per Patient: ₹715
- ROE: 16.29%
- ROCE: 23.30%
- Net Debt-to-Equity: 0.33
Infrastructure & Reach
- Diagnostic Centres: 55
- Labs: 9 (4 NABL-accredited)
- Collection Centres: 171
- CT Machines: 26
- MRI Machines: 14
- Doctors: 313
West ͏Bengal c͏o͏ntinues to drive over 9͏5% of revenues, s͏upported by͏ S͏uraksha’s hub-and-spok͏e model that bo͏o͏sts ef͏ficienc͏y͏ and sc͏ale.
S͏trategic Roadmap
S͏u͏ra͏k͏sha plans t͏o:
- Deepen presence͏ in West Bengal
- Expan͏d into North-E͏astern Ind͏ia
- G͏row medical con͏sult͏at͏ions͏
- Us͏e tech to͏ enhance patient ͏experience
- Buil͏d B2B chann͏els
- Pu͏rsu͏e targete͏d acquisi͏tions
Leadership View
Chairman & JMD Dr. Somnath Chatterjee noted, “FY25 performance underlines our integrated approach. With Fetomat onboard and our focus on clinical depth, we aim to deliver holistic diagnostics across Eastern India.”
No dividend was declared for FY25. Suraksha remains focused on sustainable, technology-driven growth across underserved regions.
Disclaimer: This content is only for informational purpose. It does not make any recommendation to act or invest. Please read the offer documents carefully before investing. Investments are subject to market risks and other risks. There is no guarantee of the actual returns that will be given.
REF: https://nsearchives.nseindia.com/corporate/SURAKSHA_29052025132108_Suraksha_Investor_Presentation_Q4__FY_2024-25.pdf
